At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens
In Brief
An observational study for Bladder Cancer. Completed, enrolled 66 participants.
Detailed Summary
Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.Despite treatment, the 5-year overall survival rates for MIBC are \<50%, with many patients unresponsive or inapt, necessitating biomarkers to select those most likely to respond or fit for treatment
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2000
Primary CompletionMar 2017
Study CompletionJun 2017
First PostedMay 2021
TodayJul 2026
First PostedMay 4, 2021
Enrollment StartMay 1, 2000
Primary CompletionMar 1, 2017
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 16.8 yearsPosted 5.2 years ago